Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid for necrotising soft-tissue infection
ACTRN12621001423808Phase 4Recruiting
- Sponsor
- Alfred Health
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in necrotizing skin infection (NSTI) comparing Tranexamic acid with Placebo (2 arms). Primary endpoints: Feasibility of a randomized trial evaluating tranexamic acid for necrotising soft-tissue infection and Reduction in extent of necrotising soft-tissue infection. Started Nov 2021; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
necrotizing skin infection (NSTI)
Beyond the preview
Go deeper on ACTRN12621001423808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001423808.